VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces Submission of US NDA for ORPATHYS plus TAGRISSO in MET Driven EGFR-Mutated Lung Cancer
Filed with HKEX · Stock code 13 ·
6ix hasn’t read this filing yet.
View original source (HKEXnews)Company analysis
Earlier from Hutchmed (china)
- VOLUNTARY ANNOUNCEMENT - HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
- HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
- HUTCHMED Reports 2026 Interim Results
- HUTCHMED to Announce 2026 Half-Year Financial Results